Rhabdomyosarcoma: Clinical Trials

121 trials for Rhabdomyosarcoma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

61 completed, 17 active not recruiting, 15 recruiting, 10 terminated. 121 Phase 2, 36 Phase 1, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 2121Completed 61, Active not recruiting 17, Recruiting 15, Terminated 10, Unknown 8, Withdrawn 5, Not yet recruiting 4, Suspended 1
Phase 136Completed 17, Recruiting 8, Terminated 4, Active not recruiting 3, Unknown 2, Not yet recruiting 1, Suspended 1
Phase 31Not yet recruiting 1

Follow Rhabdomyosarcoma: new trials by email Literature Review of Rhabdomyosarcoma trials Research Report on Rhabdomyosarcoma

Trials (filtered) newest first · largest first

All 121 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Phase 1/2 Study of CBX-12 in Children, Adolescents, or Young Adults With Solid Tumors That Have Come Back After Treatment or Are Difficult to Treat
Archive Sample Retrieval, Biospecimen Collection, pH Low Insertion Peptide-exatecan Conjugate CBX-12 - Recurrent Childhood Ewing Sarcoma, Recurrent Childhood Malignant Solid Neoplasm
Phase 1 / Phase 2Not yet recruitingChildren's Oncology Group792027-05-072026-09-22
Study Comparing Two Serums With Intense Pulsed Light for the Treatment of Moderate to Severe Photodamage and Crepiness on the Forearms
Right Arm treated with Active Re-Q Pro-Longevity Serum and Intense Pulsed Light Therapy, Left Arm treated with vehicle serum and Intense Pulsed Light Therapy - Photodamaged Skin
Phase 2 / Phase 3Not yet recruitingGoldman, Butterwick, Fitzpatrick and Groff202026-07-102026-07-07
Liposomal Irinotecan, Vincristine, Temozolomide, and Anlotinib for R/R Pediatric Solid Tumors
Liposomal Irinotecan, Vincristine, Temozolomide, and Optional Anlotinib - Relapsed or Refractory Pediatric Malignant Solid Tumors (Including Neuroblastoma, Rhabdomyosarcoma, Ewing Sarcoma, Osteosarcoma)
Phase 2Not yet recruitingTianjin Medical University Cancer Institute and Hospital332026-03-012026-03-03
Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors
Miltenyi CliniMACS Prodigy ® system, Zoledronic acid - Neuroblastoma, Rhabdomyosarcoma
Phase 1 / Phase 2RecruitingUniversity of Florida272026-02-112026-06-30
A Clinical Study on the Efficacy and Safety of All-trans Retinoic Acid Combined With VAC Regimen in the Treatment of Intermediate-to-high-risk Rhabdomyosarcoma
ATRA+VAC, ATRA+VAC+Anlotinib - Rhabdomyosarcoma
Phase 2Not yet recruitingFudan University1062026-01-012026-01-21
PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
PEEL-224, Vincristine, Temozolomide (TMZ) - Refractory Solid Tumors, Relapsed Solid Tumors
Phase 1 / Phase 2RecruitingTheodore Laetsch592025-03-232026-10-06
A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer
Cobolimab, Dostarlimab - Melanoma, Hodgkin Lymphoma
Phase 1 / Phase 2Active not recruitingGlaxoSmithKline832025-03-062025-11-12
Evaluation of the Efficacy and Safety of Pazopanib in Combination with TGI/CIV for Recurrent or Refractory Rhabdomyosarcoma in Children or Adolescents
pazopanib, TGI chemotherapy, CIV chemotherapy - Rhabdomyosarcoma, Recurrent, Refractory
Phase 2RecruitingShandong Cancer Hospital and Institute382025-02-012025-02-10
Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas
PEEL-224, Temozolomide, Vincristine - Sarcoma, Sarcoma, Ewing
Phase 1 / Phase 2RecruitingDavid S Shulman, MD632025-01-272026-02-19
Multi-cohort, Single-arm Phase II Study of Albumin-paclitaxel, Ifosfamide, and Cisplatin in the Treatment of Rare Advanced Tumors
Albumin-paclitaxel Injection - Paget Disease, Extramammary, Rhabdomyosarcoma
Phase 2RecruitingFudan University1002024-11-302024-12-20
Ivonescimab in the Treatment of Multiple Advanced Tumors
Ivocizumab - Pheochromocytoma/Paraganglioma, Rhabdomyosarcoma
Phase 2RecruitingFudan University4002024-11-202025-08-24
Vincristine and Temozolomide in Combination With PEN-866 for Adolescents and Young Adults With Relapsed or Refractory Solid Tumors
PEN-866, Vincristine, Temozolomide - Sarcoma, Ewing, Rhabdomyosarcoma
Phase 1 / Phase 2SuspendedNational Cancer Institute (NCI)642024-10-312026-03-16
Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
Silmitasertib, Irinotecan, Temozolomide - Neuroblastoma, Ewing Sarcoma
Phase 1 / Phase 2RecruitingMilton S. Hershey Medical Center1042024-10-302026-11-12
Effectiveness of Pucotenlimab Combined With Standard Chemotherapy Regimen
Pucotenlimab - Rhabdomyosarcoma, Pediatric Cancer
Phase 1 / Phase 2RecruitingSun Yat-sen University822024-06-062024-06-13
Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease
Vincristine, Dactinomycin, Cyclophosphamide - Rhabdomyosarcoma
Phase 2RecruitingSt. Jude Children's Research Hospital1352024-03-132026-11-16
Doxorubicin Hydrochloride Liposome Combined With Irinotecan (AI Regimen) Versus VIT Regimen in the Treatment of Relapsed and Refractory Pediatric Rhabdomyosarcoma: a Prospective, Open-label, Randomized Controlled, Multicenter, Phase II Clinical Study
Doxorubicin Hydrochloride Liposome+Irinotecan, Temozolomide+Irinotecan+Vincristine - Rhabdomyosarcoma, Child
Phase 2RecruitingSun Yat-sen University882023-12-302026-05-18
Personalized Vaccination in Fusion+ Sarcoma Patients (PerVision)
Peptide vaccine IPX - Ewing Sarcoma, Rhabdomyosarcoma
Phase 1 / Phase 2RecruitingUniversity Hospital Tuebingen302023-09-192026-05-04
VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors
Atezolizumab, Vincristine, Irinotecan - Solid Tumor, Rhabdomyosarcoma
Phase 1 / Phase 2Active not recruitingUniversity of Texas Southwestern Medical Center232023-04-182026-11-04
Radiotherapy Combined With Realgar-Indigo Naturalis Formula (RIF) in the Treatment of Rhabdomyosarcoma(RMS) in Children
Realgar-Indigo Naturalis Formulation, Radiotherapy - Rhabdomyosarcoma, Child
Phase 2UnknownXinhua Hospital, Shanghai Jiao Tong University School of Medicine532023-01-312023-02-01
A Pilot Study of Thermodox and MR-HIFU for Treatment of Relapsed Solid Tumors
Magnetic Resonance-Guided High Intensity Focused Ultrasound, Lyso-thermosensitive Liposomal Doxorubicin - Solid Tumors, Soft Tissue Sarcoma
Phase 2WithdrawnChildren's National Research Institute2022-11-102025-01-01

Showing 20 of 121. Sign in to see all of them.

Narrower conditions

Sarcoma (68)  ·  Sarcoma, Ewing (55)  ·  Osteosarcoma (53)  ·  Neuroblastoma (46)  ·  Neuroectodermal Tumors, Primitive, Peripheral (29)  ·  Wilms Tumor (25)  ·  Medulloblastoma (24)  ·  Sarcoma, Synovial (24)  ·  Liposarcoma (22)  ·  Leiomyosarcoma (21)  ·  Ependymoma (20)  ·  Hepatoblastoma (20)  ·  Rhabdoid Tumor (20)  ·  Fibrosarcoma (19)

Broader conditions

Neoplasms by Histologic Type (121)  ·  Neoplasms, Muscle Tissue (121)  ·  Myosarcoma (120)  ·  Neoplasms, Connective and Soft Tissue (119)  ·  Neoplasms (112)  ·  Neoplasms, Connective Tissue (91)  ·  Neoplasms, Nerve Tissue (77)  ·  Neoplasms, Bone Tissue (72)  ·  Neoplasms, Glandular and Epithelial (64)  ·  Neoplasms, Germ Cell and Embryonal (62)  ·  Neuroectodermal Tumors (61)  ·  Neoplasms, Neuroepithelial (57)  ·  Neoplasms by Site (54)  ·  Neuroectodermal Tumors, Primitive (53)  ·  Sarcoma (53)

Interventions

Temozolomide (15)  ·  Vincristine (15)  ·  Irinotecan (13)  ·  Cyclophosphamide (12)  ·  Doxorubicin (7)  ·  Filgrastim (7)  ·  Dactinomycin (6)  ·  Etoposide (6)  ·  Ifosfamide (6)  ·  Magnetic Resonance Spectroscopy (6)  ·  Gemcitabine (5)  ·  Phantoms, Imaging (5)  ·  Specimen Handling (5)  ·  Vinorelbine (5)  ·  X-Rays (5)

Sponsors

National Cancer Institute (NCI) (31)  ·  European Organisation for Research and Treatment of Cancer - EORTC (7)  ·  St. Jude Children's Research Hospital (6)  ·  Memorial Sloan Kettering Cancer Center (5)  ·  Children's Oncology Group (4)  ·  Eisai Inc. (3)  ·  Eli Lilly and Company (3)  ·  Fudan University (3)  ·  Brown University (2)  ·  Children's National Research Institute (2)  ·  City of Hope Medical Center (2)  ·  H. Lee Moffitt Cancer Center and Research Institute (2)  ·  Novartis Pharmaceuticals (2)  ·  Sarcoma Alliance for Research through Collaboration (2)  ·  Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (2)

Countries

United States (89)  ·  Canada (19)  ·  Puerto Rico (15)  ·  Australia (14)  ·  France (14)  ·  Germany (11)  ·  Spain (10)  ·  Italy (9)  ·  United Kingdom (9)  ·  Belgium (8)  ·  Netherlands (8)  ·  China (6)  ·  Denmark (5)  ·  Switzerland (5)  ·  New Zealand (4)

Top investigators

Robert Maki, MD, PhD (3)  ·  AeRang Kim, MD, PhD (2)  ·  Christine M Heske, M.D. (2)  ·  Hongxia Wang, Doctor (2)  ·  AeRang Kim (1)  ·  Alberto Pappo, MD (1)  ·  Alberto S. Pappo, MD (1)  ·  Alok Kothari, M.D. (1)  ·  Andrea T Franson (1)  ·  Antonio Casado (1)  ·  Arhanti Sadanand, MD (1)  ·  Axel Le Cesne, MD (1)

Results publications

PMID 31401903, PMID 11705489, PMID 12528778, PMID 12957454, PMID 15010069, PMID 15177491, PMID 15592836, PMID 15659504, PMID 16528479, PMID 17095209, PMID 17109446, PMID 17264331, PMID 17336054, PMID 18676758, PMID 19088049, PMID 19451429, PMID 19451433, PMID 20471824, PMID 21896345, PMID 22682017, PMID 23382028, PMID 24215845, PMID 28950372, PMID 29216400, PMID 29567632, PMID 29669701, PMID 30410720, PMID 31013172, PMID 31513481, PMID 31575518, PMID 31987969, PMID 32192573, PMID 32554315, PMID 32701199, PMID 33305087, PMID 33591402, PMID 34004576, PMID 34343032, PMID 34392187, PMID 34486544, PMID 35353553, PMID 35483358, PMID 37178647, PMID 37398992, PMID 38815151, PMID 38873934, PMID 38935895, PMID 39298716, PMID 40313040, PMID 40937822

NIH funding

U10CA180886 (15), U10CA098543 (6), P30CA008748 (2), P30CA033572 (2), UM1CA097452 (2), UM1CA228823 (2), 2014 (1), 2016 (1), 2017 (1), 2018 (1), 2019 (1), 2023 (1), N01CM62203 (1), N01CM62206 (1), P01CA225618 (1)